Home > Oncology > ASCO 2019 > Melanoma > Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma

Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma

Presented By
Prof. Mario MandalĂ , Papa Giovanni XXIII Cancer Centre Hospital, Bergamo, Italy
Conference
ASCO 2019
Trial
CheckMate 238
Medical writer: Dr. Rachel H. Giles Prof. Mario MandalĂ  (Papa Giovanni XXIII Cancer Centre Hospital, Bergamo, Italy) provided data from CheckMate 238 plotting treatment-related adverse events (TRAEs) for nivolumab in patients with resected stage IIIB/C or IV melanoma against recurrence-free survival (RFS). His comprehensive analysis demonstrated a safety profile consistent with the other nivolumab studies. The majority of TRAEs with adjuvant NIVO occurred early during treatment, and patients had a reduced frequency of TRAEs after the treatment course. Most TRAEs resolved within 3 months [1]. CheckMate 238 demonstrated that adjuvant treatment with nivolumab significantly improved RFS for patients with stage III/IV melanoma with pathologic involvement of regional lymph nodes >1 mm who have undergone complete resection including total lymphadenectomy, reducing the risk of recurrence or death by 35% compared with ipilimumab (HR, 0.65; 97.56% CI, 0.53-0.80; P...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on